You are leaving our website

or Decline

2022 Annual Report

Annual Report 2022

Financial highlights

172.0 £m See-through Revenue*
30.3 £m Underlying Profit Before Tax
4.28p Underlying Basic EPS
167.4 £m Statutory Revenue
5.2 £m Reported Profit Before Tax

*Non-IFRS alternative performance measures. See-through revenue includes sales from Nizoral as if they had been invoiced by Alliance. For statutory accounting purposes the product margin on Nizoral sales is included within Revenue, in line with IFRS 15.

Results centre



We are Alliance

Download the Overview (573kb)

Peter Butterfield, Chief Executive Officer

CEO's Review

Highly strategic US acquisition completed; strategy refreshed, and Board strengthened

Download the CEO's Review (2.0mb)

Andrew Franklin, Chief Financial Officer

Financial Review

Performance impacted by specific business challenges

Download the Financial Review (2.1mb)



Continuing our journey to become a more sustainable business

Download Sustainability (614kb)